Literature DB >> 15465721

Effectiveness of antagonists for tiletamine-zolazepam/xylazine immobilization in female white-tailed deer.

Brad F Miller1, Lisa I Muller, Tom Doherty, David A Osborn, Karl V Miller, Robert J Warren.   

Abstract

A combination of tiletamine-zolazepam/xylazine (TZ/X) is effective in the chemical immobilization of white-tailed deer (Odocoileus virginianus); however, the lengthy duration of immobilization may limit its usefulness. From October to November 2002, 21 captive female deer were assigned randomly to an alpha(2) antagonist treatment to reverse xylazine-induced sedation (seven does per group). All deer were given 220 mg of TZ (4.5+/-0.4 mg/kg) and 110 mg of X (2.2+/-0.2 mg/kg) intramuscularly (IM). Antagonist treatments were either 200 mg of tolazoline (4.0+/-0.4 mg/kg), 11 mg of atipamezole (0.23+/-0.02 mg/kg), or 15 mg of yohimbine (0.30+/-0.02 mg/kg) injected, half intravenously and half subcutaneously, 45 min after the IM TZ/X injection. In addition, 10 other deer (five per group) were immobilized as before and then given tolazoline (200 mg) after 45 min, with either a carrier (dimethyl sulfoxide [DMSO]) or carrier (DMSO) plus flumazenil (5 mg) to reverse the zolazepam portion of TZ. Mean times from antagonist injection until a deer raised its head were different for alpha(2) antagonist treatments (P=0.02). Times were longer for yohimbine (62.3+/-42.7 min) than for either atipamezole (24.3+/-17.1 min) or tolazoline (21.3+/-14.3 min). Mean times from antagonist injection until standing were not different (P=0.15) among yohimbine (112.0+/-56.4 min), atipamezole (89.7+/-62.8 min), or tolazoline (52.6+/-37.2 min). A sedation score based on behavioral criteria was assigned to each deer every 30 min for 5 hr. On the basis of sedation scores, tolazoline resulted in a faster and more complete reversal of immobilization. Flumazenil treatment did not affect recovery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465721     DOI: 10.7589/0090-3558-40.3.533

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  7 in total

1.  Comparison of Atipamezole with Yohimbine for Antagonism of Xylazine in Mice Anesthetized with Ketamine and Xylazine.

Authors:  Christopher F Janssen; Pauline Maiello; M Jerry Wright; Kara B Kracinovsky; Joseph T Newsome
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

2.  Protocol for Assessing the Relative Effects of Environment and Genetics on Antler and Body Growth for a Long-lived Cervid.

Authors:  Eric S Michel; Emily B Flinn; Stephen Demarais; Bronson K Strickland; Guiming Wang; Chad M Dacus
Journal:  J Vis Exp       Date:  2017-08-08       Impact factor: 1.355

3.  Birth date promotes a tortoise or hare tactic for body mass development of a long-lived male ungulate.

Authors:  Eric S Michel; Stephen Demarais; Bronson K Strickland; Guiming Wang
Journal:  Oecologia       Date:  2017-11-21       Impact factor: 3.225

4.  Characterization of two MHC II genes (DOB, DRB) in white-tailed deer (Odocoileus virginianus).

Authors:  Natascha M D Ivy-Israel; Carolyn E Moore; Tonia S Schwartz; Stephen S Ditchkoff
Journal:  BMC Genet       Date:  2020-07-29       Impact factor: 2.797

5.  Contrasting the Effects of Maternal and Behavioral Characteristics on Fawn Birth Mass in White-Tailed Deer.

Authors:  Eric S Michel; Stephen Demarais; Bronson K Strickland; Jerrold L Belant
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

6.  Improved nutrition cues switch from efficiency to luxury phenotypes for a long-lived ungulate.

Authors:  Eric S Michel; Emily B Flinn; Stephen Demarais; Bronson K Strickland; Guiming Wang; Chad M Dacus
Journal:  Ecol Evol       Date:  2016-09-22       Impact factor: 2.912

7.  Azaperone and xylazine: A pharmacological combination to facilitate captive deer management for red brocket deer (Mazama americana).

Authors:  Adriano B Carregaro; Bárbara G Ferrari; André N E da Silva; Nathalia V Xavier; José M B Duarte
Journal:  PLoS One       Date:  2019-08-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.